Patient clinical data
Xenograft . | Age at diagnosis, in months/sex . | ALL subtype . | Disease status at biopsy . | Length of CR1, in months . | Site of relapse . | Survival after first relapse, in months . | Current clinical status . |
|---|---|---|---|---|---|---|---|
| ALL-2 | 65/F | c-ALL | Relapse 3 | 30 | BM/CNS | 46 | DOD |
| ALL-3 | 154/F | Pre-B | Diagnosis | 38 | BM | 93* | CR2 |
| ALL-4 | 105/M | Ph+, c-ALL | Diagnosis | 10 | BM | 1 | DOD |
| ALL-7 | 88/M | Biphen | Diagnosis | 7 | BM | 6 | DOD |
| ALL-8 | 152/M | T-ALL | Relapse 1 | 17 | BM | 1 | DOD |
| ALL-10 | 48/M | c-ALL | Diagnosis | 57* | — | — | CR1 |
| ALL-11 | 37/F | c-ALL | Diagnosis | 120* | — | — | CR1 |
| ALL-16 | 122/F | T-ALL | Diagnosis | 103* | — | — | CR1 |
| ALL-17 | 107/F | c-ALL | Diagnosis | 25 | CNS | 31* | CR2 |
| ALL-19 | 194/M | c-ALL | Relapse 1 | 4 | BM | 7 | DOD |
Xenograft . | Age at diagnosis, in months/sex . | ALL subtype . | Disease status at biopsy . | Length of CR1, in months . | Site of relapse . | Survival after first relapse, in months . | Current clinical status . |
|---|---|---|---|---|---|---|---|
| ALL-2 | 65/F | c-ALL | Relapse 3 | 30 | BM/CNS | 46 | DOD |
| ALL-3 | 154/F | Pre-B | Diagnosis | 38 | BM | 93* | CR2 |
| ALL-4 | 105/M | Ph+, c-ALL | Diagnosis | 10 | BM | 1 | DOD |
| ALL-7 | 88/M | Biphen | Diagnosis | 7 | BM | 6 | DOD |
| ALL-8 | 152/M | T-ALL | Relapse 1 | 17 | BM | 1 | DOD |
| ALL-10 | 48/M | c-ALL | Diagnosis | 57* | — | — | CR1 |
| ALL-11 | 37/F | c-ALL | Diagnosis | 120* | — | — | CR1 |
| ALL-16 | 122/F | T-ALL | Diagnosis | 103* | — | — | CR1 |
| ALL-17 | 107/F | c-ALL | Diagnosis | 25 | CNS | 31* | CR2 |
| ALL-19 | 194/M | c-ALL | Relapse 1 | 4 | BM | 7 | DOD |
Biphen indicates biphenotypic; BM, bone marrow; c-ALL, common (CD10+) ALL; CNS, central nervous system; CR1, alive in first complete remission; CR2 alive in second complete remission; DOD, dead of disease; Ph+, Philadelphia chromosome—positive ALL; and —, no relapse.
No event (censored).